Royalty Pharma plc Class A Ordinary Shares vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.91 (market cap $3.39B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 7.5× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| RPRX | SPUS | |
|---|---|---|
Market Cap | $25.27B | $3.39B |
Volume | 3,671,183 | 356,227 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.96 | $61.15 |
52-Week Low | $35.44 | $46.65 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →